Linked Life Data

9818753

Source:http://linkedlifedata.com/resource/pubmed/id/9818753

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1999-2-16
pubmed:abstractText
The principal aim of this study was to evaluate the in-vitro activity of new quinolones against clinical strains of Streptococcus pneumoniae. Four hundred and fifty-two single clinical isolates (of which 362 were susceptible to penicillin, 54 intermediate and 36 highly resistant) were tested against penicillin, cefuroxime, ciprofloxacin, levofloxacin, trovafloxacin and Bay 12-8039. Of the tested S. pneumoniae strains, 97.1 % had MICs of trovafloxacin of < or = 0.25 mg/L, and 96.7% had MICs of Bay 12-8039 of < or = 0.25 mg/L (difference not statistically significant); 81.9% of strains had MICs of cefuroxime of < or = 0.25 mg/L (P < or = 0.001 against both quinolones). Only 4% and 0.7% of the strains had MICs of levofloxacin and ciprofloxacin respectively of < or = 0.25 mg/L. Compared with older quinolones, trovafloxacin and Bay 12-8039 have good in-vitro activity against S. pneumoniae.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0305-7453
pubmed:author
pubmed:issnType
Print
pubmed:volume
42
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
523-5
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1998
pubmed:articleTitle
Comparative activity of trovafloxacin and Bay 12-8039 against 452 clinical isolates of Streptococcus pneumoniae.
pubmed:affiliation
Department of Infectious Diseases and Microbiology, Hôpital Maisonneuve-Rosemont, University of Montreal, Québec, Canada. weissk@microim.umontreal.ca
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't